Amicus Therapeutics
Engaged Employer
Add Review

Amicus Therapeutics Reviews

Rating Trends
Recommend to a friend
Approve of CEO
Amicus Therapeutics President, CEO and Director John F. Crowley
John F. Crowley
7 Ratings
  • Excellent learning environment

    • Work/Life Balance
    • Culture & Values
    • Career Opportunities
    • Comp & Benefits
    • Senior Management
    Former Intern - In-vivo Pharmacology Co-op in Cranbury, NJ
    Former Intern - In-vivo Pharmacology Co-op in Cranbury, NJ

    I worked at Amicus Therapeutics as an intern (Less than a year)

    Neutral Outlook
    Approves of CEO
    Neutral Outlook
    Approves of CEO


    As a newbie co-op, this was a great place to learn a wide variety of technical skills in addition to gaining exposure to a healthy small pharma culture. As a small, growing company, the enthusiasm was palpable and was invaluable for me as a developing researcher.


    An understandable consequence of starting at the bottom of the food chain was a lack of understanding the development strategies trickling down from the top.

    Advice to Management

    Stay hungry.

Amicus Therapeutics Interviews

Interview Experience

Interview Experience


Getting an Interview

Getting an Interview


Interview Difficulty


Interview Difficulty




    Research Associate Interview

    Anonymous Interview Candidate in Cranbury, NJ
    Accepted Offer
    Positive Experience
    Easy Interview


    I applied through a recruiter. The process took a weekinterviewed at Amicus Therapeutics (Cranbury, NJ).


    The group that I was interviewing with was very friendly. No presentation was needed. Half a day interview that included 1:1 with upper level directors and group panels with PhD scientist and RAs.

Amicus Therapeutics Awards & Accolades

Something missing? Add an award
Best Places to Work in New Jersey (Small/Medium), Best Companies Group, 2009

Additional Info

Unlock Profile
Headquarters Cranbury, NJ
Size 50 to 149 Employees
Founded Unknown
Type Company - Public (FOLD)
Industry Biotech & Pharmaceuticals
Revenue Less than $1 million (USD) per year

Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. Unlike other treatments which replace defective enzymes, Amicus uses small molecule pharmacological "chaperones" which bind to a patient's own defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease. Another candidate, Plicera, is in development to treat Gaucher disease, while a third candidate, AT2220 is targeting Pompe disease. The company is also researching treatments for neurodegenerative... More

Work at Amicus Therapeutics? Share Your Experiences

Amicus Therapeutics

Click to Rate